Aspirin Use Post-Acute Coronary Syndromes: Intolerance, Bleeding and Discontinuation

[1]  L. Bouter,et al.  Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. , 2002, Kidney international.

[2]  V. Hasselblad,et al.  Seeking the optimal aspirin dose in acute coronary syndromes. , 2002, The American journal of cardiology.

[3]  S. Borzak,et al.  Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. , 2002, American heart journal.

[4]  R. Califf,et al.  Patient-reported frequency of taking aspirin in a population with coronary artery disease. , 2002, The American journal of cardiology.

[5]  R. Califf,et al.  Underuse of aspirin in a referral population with documented coronary artery disease. , 2002, The American journal of cardiology.

[6]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[7]  S. Hernández-Díaz,et al.  Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. , 2001, British journal of clinical pharmacology.

[8]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[9]  Second Symphony Investigators.  Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes , 2001, Circulation.

[10]  A. Gawlinski,et al.  Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). , 2001, The American journal of cardiology.

[11]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[12]  Y. Loke,et al.  Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis , 2000, BMJ : British Medical Journal.

[13]  R. Stafford,et al.  Aspirin use is low among United States outpatients with coronary artery disease. , 2000, Circulation.

[14]  R. Califf,et al.  Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial , 2000, The Lancet.

[15]  G. Remuzzi,et al.  Uremic bleeding: closing the circle after 30 years of controversies? , 1999, Blood.

[16]  L. Newby,et al.  Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary sYndromes (SYMPHONY) trial , 1999 .

[17]  W. Aronow.  Underutilization of Aspirin in Older Patients with Prior Myocardial Infarction at the Time of Admission to a Nursing Home , 1998, Journal of the American Geriatrics Society.

[18]  C. Bode,et al.  Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. , 1998, Circulation.

[19]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[20]  P. Metcalf,et al.  Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. , 1996, American heart journal.

[21]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[22]  J. Stamler,et al.  Effect of nitric oxide synthase inhibition on bleeding time in humans. , 1995, Journal of cardiovascular pharmacology.

[23]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[24]  G. Hedenstierna,et al.  Bleeding time prolongation and NO inhalation , 1993, The Lancet.

[25]  C. Cierniewski,et al.  The Decreased Circulating Platelet Mass and Its Relation to Bleeding Time in Chronic Renal Failure , 1991, Thrombosis and Haemostasis.

[26]  N. Perico,et al.  Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. , 1990, The Journal of clinical investigation.

[27]  S. Moncada,et al.  An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Sixma,et al.  High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. , 1990, Blood.

[29]  S. Moncada,et al.  ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM , 1987, The Lancet.

[30]  M. Bonati,et al.  Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. , 1987, The Journal of clinical investigation.

[31]  C. Brown,et al.  Evidence against a platelet cyclooxygenase defect in uraemic subjects on chronic haemodialysis , 1986, British journal of haematology.

[32]  G. Levy.  Pharmacokinetics of salicylate in man. , 1979, Drug metabolism reviews.

[33]  G. Levy,et al.  Salicylate accumulation kinetics in man. , 1972, The New England journal of medicine.

[34]  G. Levy,et al.  Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man , 1972, Clinical pharmacology and therapeutics.